Webinar: Ex Vivo Drug Response Profiling in Clinical Application

Ex vivo drug response profiling has emerged as a promising tool for studying genotype–drug response associations, offering the potential for precision medicine, especially in cancer treatment. In this webinar, Peter-Martin Bruch will discuss the findings from the SMARTrial (NCT03488641), a prospective non-interventional trial that investigated the feasibility of ex vivo drug response profiling for guiding treatment decisions in hematologic malignancies. With a 91% of study results delivered within seven days, the trial highlighted the feasibility of this approach. More importantly, it showed in vivo therapy response beyond known genetic risk factors, demonstrating how functional profiling can enhance risk stratification and treatment personalization beyond traditional genetic markers.